Enliven Therapeutics, Inc. (ELVN)
ELVN moved a median of +0.10% 30 minutes after news, and +0.09% by the close. How ELVN actually reacts to news — the realized, point-in-time move the market made, measured across 398 labeled events over the last three years with zero look-ahead.
ELVN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.07% | 51% | 398 |
| 30-min | +0.10% | 52% | 398 |
| 60-min | -0.10% | 46% | 398 |
| to close | +0.09% | 50% | 389 |
| Middle 50% of ELVN reactions | -1.23% to +1.36% |
|---|---|
| Median reaction (30-min) | +0.10% |
| Measured reactions | 398 |
Half of all Enliven Therapeutics, Inc. news events land between -1.23% and +1.36% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ELVN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 27 | -0.35% | 26% | +0.47% |
| Rating reiterations | 23 | +0.37% | 61% | +0.47% |
| Price-target raises | 14 | +0.35% | 57% | +0.63% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ELVN ranks against every other measured name →
That’s how ELVN usually reacts — get an email when it moves on news →Email me when ELVN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ELVN's baseline. Nothing else.
Recent ELVN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Press release | PR Newswire | -0.28% | -0.38% | |
| Form 8-K Enliven Therapeutics, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | -0.38% | |
| Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia | Press release | PR Newswire | +0.31% | -0.63% | |
| Enliven Therapeutics to Present at Upcoming Investor Conferences | Press release | PR Newswire | +0.34% | -0.62% | |
| Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting | Press release | PR Newswire | +0.02% | -0.22% | |
| Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Press release | PR Newswire | +0.37% | +1.57% | |
| Form 10-Q Enliven Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.37% | +1.57% | |
| Form 8-K Enliven Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | +1.57% | |
| Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares | Press release | PR Newswire | -0.03% | +0.09% | |
| Form 8-K Enliven Therapeutics, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | -7.17% | |
| Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | Press release | PR Newswire | -0.39% | +15.12% | |
| Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | PR Newswire | -0.39% | +15.12% | |
| Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components | Press release | PR Newswire | -4.51% | -10.31% | |
| Form 8-K Enliven Therapeutics, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -4.51% | -10.31% | |
| Form 8-K Enliven Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | +3.61% | |
| Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress | Press release | PR Newswire | -0.19% | -1.42% | |
| Enliven Therapeutics to Present at Upcoming Investor Conferences | Press release | PR Newswire | +0.19% | -2.97% | |
| Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | Press release | PR Newswire | +0.88% | +4.99% | |
| Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Press release | PR Newswire | -0.23% | -2.60% | |
| Form 10-Q Enliven Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.23% | -2.60% | |
| Form 8-K Enliven Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | -2.60% | |
| Form ARS Enliven Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.03% | -4.15% | |
| Form DEF 14A Enliven Therapeutics, For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -0.03% | -4.15% | |
| Form DEFA14A Enliven Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.03% | -4.15% | |
| Form PRE 14A Enliven Therapeutics, For: Jun 09 | SEC filing · Form PRE | SEC EDGAR | -0.84% | +3.42% | |
| Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | Press release | PR Newswire | +0.00% | +4.86% | |
| Form 10-K Enliven Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +4.86% | |
| Form 8-K Enliven Therapeutics, For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.86% | |
| Form S-8 Enliven Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +4.86% | |
| Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference | Press release | PR Newswire | -0.39% | +0.27% | |
| Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Press release | PR Newswire | +19.75% | +39.98% | |
| Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development | Press release | PR Newswire | +1.12% | +2.18% | |
| Form 8-K Enliven Therapeutics, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +1.12% | +2.18% | |
| Form S-8 Enliven Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.77% | -5.49% | |
| Enliven Therapeutics Announces New CEO to Drive Next Phase of Development | Press release | PR Newswire | -0.85% | -6.10% | |
| Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules | Press release | PR Newswire | -0.40% | -9.84% | |
| Form 8-K Enliven Therapeutics, For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | -0.85% | -6.10% | |
| Form 8-K/A Enliven Therapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | — | |
| Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | Press release | PR Newswire | +0.61% | — | |
| Form 10-Q Enliven Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.61% | — | |
| Form 8-K Enliven Therapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | — | |
| Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting | Press release | PR Newswire | -3.44% | -13.98% | |
| Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting | Press release | PR Newswire | +0.85% | +1.35% | |
| Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Press release | PR Newswire | +1.08% | -0.85% | |
| Form 10-Q Enliven Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.08% | -0.85% | |
| Form 8-K Enliven Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.08% | -0.85% | |
| Form S-3ASR Enliven Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | +1.08% | -0.85% | |
| Form 8-K Enliven Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | -0.32% | |
| Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares | Press release | PR Newswire | +1.76% | -4.26% | |
| Form 8-K Enliven Therapeutics, For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | -1.24% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ELVN section they belong to.
Where else ELVN is measured.
ELVN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Enliven Therapeutics, Inc.'s median reaction calculated?
Every labeled ELVN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 398 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of ELVN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ELVN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.